{"id":60021,"date":"2026-03-19T21:35:07","date_gmt":"2026-03-19T13:35:07","guid":{"rendered":"https:\/\/flcube.com\/?p=60021"},"modified":"2026-03-19T21:35:08","modified_gmt":"2026-03-19T13:35:08","slug":"sanofis-venglustat-wins-fda-breakthrough-therapy-designation-oral-brain-penetrant-gcsi-targets-gaucher-disease-type-3-neurological-symptoms","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60021","title":{"rendered":"Sanofi&#8217;s Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms"},"content":{"rendered":"\n<p><strong>Sanofi<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced that <strong>venglustat<\/strong> received <strong>Breakthrough Therapy Designation (BTD)<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of <strong>neurological symptoms of Gaucher disease type 3 (GD3)<\/strong>. The investigational <strong>oral, brain-penetrant glucosylceramide synthase inhibitor (GCSi)<\/strong> represents a potential <strong>disease-modifying approach<\/strong> to address the <strong>central nervous system manifestations<\/strong> of this rare lysosomal storage disorder.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td><strong>Breakthrough Therapy Designation (BTD)<\/strong><\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Venglustat (investigational oral GCSi)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Sanofi (NASDAQ: SNY)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neurological symptoms of <strong>Gaucher disease type 3 (GD3)<\/strong><\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>Expedited development and review pathway for serious conditions with preliminary clinical evidence of substantial improvement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism\">Product Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Venglustat Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td><strong>Glucosylceramide synthase inhibitor (GCSi)<\/strong> \u2013 blocks first step in glycosphingolipid (GSL) synthesis<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td><strong>Oral, brain-penetrant<\/strong> \u2013 crosses blood-brain barrier to address CNS pathology<\/td><\/tr><tr><td><strong>Target Pathology<\/strong><\/td><td>Abnormal GSL accumulation and its pathophysiological consequences in GD3<\/td><\/tr><tr><td><strong>Therapeutic Goal<\/strong><\/td><td><strong>Slow disease progression<\/strong> by reducing substrate burden vs. enzyme replacement therapy (ERT) which does not cross BBB<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Disease Context:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gaucher Disease Type 3:<\/strong> Chronic neuronopathic form with <strong>neurological deterioration<\/strong> (oculomotor apraxia, seizures, cognitive decline) not addressed by standard ERT<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> No approved therapies specifically target CNS manifestations; substrate reduction therapy (SRT) with brain penetration represents potential paradigm shift<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-impact\">Strategic Context &amp; Market Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>GD3 Prevalence<\/strong><\/td><td><strong>~5,000\u20138,000 patients globally<\/strong>; ultra-rare indication with high unmet need supports premium pricing<\/td><\/tr><tr><td><strong>Oral CNS-Penetrant Advantage<\/strong><\/td><td>vs. bi-weekly IV ERT (imiglucerase) and oral non-CNS SRT (eliglustat); venglustat addresses neurological decline<\/td><\/tr><tr><td><strong>Breakthrough Designation Value<\/strong><\/td><td><strong>Intensive FDA guidance<\/strong>, <strong>rolling review eligibility<\/strong>, <strong>priority review voucher potential<\/strong> \u2013 accelerates timeline by 6\u201312 months<\/td><\/tr><tr><td><strong>Sanofi Rare Disease Strategy<\/strong><\/td><td>Complements existing Gaucher franchise (Cerezyme, Cerdelga) with <strong>next-generation CNS-targeted approach<\/strong><\/td><\/tr><tr><td><strong>Revenue Potential<\/strong><\/td><td>Peak sales <strong>$300\u2013500 million annually<\/strong> assuming approval in GD3 and potential expansion to other neuronopathic GSL storage disorders (GM2 gangliosidosis)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Status:<\/strong> Phase II\/III data supporting BTD likely from <strong>MOVES trial<\/strong> (ongoing in GD3); pivotal readout expected <strong>2027<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> BTD enables <strong>real-time FDA feedback<\/strong> on Phase III design; potential for <strong>accelerated approval<\/strong> based on surrogate biomarker (plasma GSL reduction)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial potential for venglustat in Gaucher disease type 3. Actual results may differ due to Phase III trial outcomes, competitive dynamics with substrate reduction therapies, and reimbursement negotiations for ultra-rare disease treatments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":60024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,867,24,147],"class_list":["post-60021","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-nasdaq-sny","tag-rare-orphan-disease-drugs","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi&#039;s Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of neurological symptoms of Gaucher disease type 3 (GD3). The investigational oral, brain-penetrant glucosylceramide synthase inhibitor (GCSi) represents a potential disease-modifying approach to address the central nervous system manifestations of this rare lysosomal storage disorder.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60021\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi&#039;s Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of neurological symptoms of Gaucher disease type 3 (GD3). The investigational oral, brain-penetrant glucosylceramide synthase inhibitor (GCSi) represents a potential disease-modifying approach to address the central nervous system manifestations of this rare lysosomal storage disorder.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60021\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-19T13:35:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-19T13:35:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi&#8217;s Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms\",\"datePublished\":\"2026-03-19T13:35:07+00:00\",\"dateModified\":\"2026-03-19T13:35:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021\"},\"wordCount\":404,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1901.webp\",\"keywords\":[\"Breakthrough therapy\",\"NASDAQ: SNY\",\"Rare \\\/ orphan disease drugs\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60021#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60021\",\"name\":\"Sanofi's Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1901.webp\",\"datePublished\":\"2026-03-19T13:35:07+00:00\",\"dateModified\":\"2026-03-19T13:35:08+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of neurological symptoms of Gaucher disease type 3 (GD3). The investigational oral, brain-penetrant glucosylceramide synthase inhibitor (GCSi) represents a potential disease-modifying approach to address the central nervous system manifestations of this rare lysosomal storage disorder.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60021\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi's Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60021#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi&#8217;s Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi's Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of neurological symptoms of Gaucher disease type 3 (GD3). The investigational oral, brain-penetrant glucosylceramide synthase inhibitor (GCSi) represents a potential disease-modifying approach to address the central nervous system manifestations of this rare lysosomal storage disorder.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60021","og_locale":"en_US","og_type":"article","og_title":"Sanofi's Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms","og_description":"Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of neurological symptoms of Gaucher disease type 3 (GD3). The investigational oral, brain-penetrant glucosylceramide synthase inhibitor (GCSi) represents a potential disease-modifying approach to address the central nervous system manifestations of this rare lysosomal storage disorder.","og_url":"https:\/\/flcube.com\/?p=60021","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-19T13:35:07+00:00","article_modified_time":"2026-03-19T13:35:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60021#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60021"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi&#8217;s Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms","datePublished":"2026-03-19T13:35:07+00:00","dateModified":"2026-03-19T13:35:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60021"},"wordCount":404,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=60021#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1901.webp","keywords":["Breakthrough therapy","NASDAQ: SNY","Rare \/ orphan disease drugs","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60021#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60021","url":"https:\/\/flcube.com\/?p=60021","name":"Sanofi's Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=60021#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=60021#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1901.webp","datePublished":"2026-03-19T13:35:07+00:00","dateModified":"2026-03-19T13:35:08+00:00","description":"Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of neurological symptoms of Gaucher disease type 3 (GD3). The investigational oral, brain-penetrant glucosylceramide synthase inhibitor (GCSi) represents a potential disease-modifying approach to address the central nervous system manifestations of this rare lysosomal storage disorder.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60021#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60021"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=60021#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1901.webp","width":1080,"height":608,"caption":"Sanofi's Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60021#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi&#8217;s Venglustat Wins FDA Breakthrough Therapy Designation \u2013 Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60021"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60021\/revisions"}],"predecessor-version":[{"id":60025,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60021\/revisions\/60025"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/60024"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}